News & Updates
Filter by Specialty:
Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC
Use of anlotinib combined with etoposide and carboplatin (EC; chemotherapy) as first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) yields a significantly improved progression-free survival (PFS) as well as overall survival (OS) benefits when compared with chemotherapy, according to data from the phase III ETER701 trial presented at ELCC 2024.
Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC
18 Apr 2024Is salt substitution really good for the heart?
A recent study has shown the benefits of salt substitution in reducing all-cause or cardiovascular (CV) mortality. However, the evidence remains unclear as regards lowering CV events and not increasing serious adverse events, specifically in a Western population.
Is salt substitution really good for the heart?
18 Apr 2024Progressive resistance training not superior to neuromuscular exercise for hip OA
Progressive resistant training (PRT) does not seem to work better than neuromuscular exercise (NEMEX) for easing hip pain and improving functional performance or hip-related quality of life (QoL) in patients with hip osteoarthritis (OA), reports a recent study.